BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology...
Cancer
Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4
Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...
Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030
The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...
Mabwell Bioscience Enters Licensing Agreement with Laboratorios Legrand for Biosimilars in Colombia and Ecuador
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a strategic licensing agreement with...
HutchMed and Takeda Submit Fruquintinib NDA for Metastatic CRC in Japan
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that its partner Takeda (TYO: 4502) has...
Sichuan Biokin’s IZalontamab Gets US FDA Greenlight for NSCLC Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Innovent Biologics Withdraws Parsaclisib Filing in China, Halts Development
Innovent Biologics Inc., a leading China-based biotech company (HKG: 1801), has announced the voluntary withdrawal...
Jiangsu Hengrui Licenses Pyrotinib to Dr. Reddy’s for Indian Market
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has entered into a licensing agreement with...
Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio
Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma...
Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results
Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...
PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...
Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan
Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...
Transcenta Secures FDA Approval for Phase III Trial of Osemitamab
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...
CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...
RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy
China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...
Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...
Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009
Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...
Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...
BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02
BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...
Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China
The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...